Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries

2.50
Hdl Handle:
http://hdl.handle.net/2336/47361
Title:
Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries
Authors:
Schroeder, H; Gustafsson, G; Saarinen-Pihkala, U M; Glomstein, A; Jonmundsson, G; Nysom, K; Ringden, O; Mellander, L
Citation:
Bone Marrow Transplant. 1999, 23(6):555-60
Issue Date:
1-Mar-1999
Abstract:
This study compares allogeneic BMT with conventional chemotherapy for childhood ALL in second remission. Seventy-five children were transplanted between July 1981 and December 1995. For each patient two control patients matching the following criteria were selected from the Nordic database of ALL: (1) time of diagnosis, (2) T vs. non-T ALL, (3) site of relapse, (4) initial risk group, (5) sex and (6) relapse < or > or =6 months after cessation of therapy. The minimal time of follow-up was 24 months. Mortality rate in CR2, leukemic relapse rate and the proportion in continued second remission were 16/75 (21%), 22/75 (29%) and 37/75 (50%), respectively. P2.-EFS for the BMT group was significantly better than that for the control group (0.40 vs. 0.23, P = 0.02). Children transplanted for bone marrow relapses in particular had a higher P2.-EFS (0.35 vs. 0.15 for the control group, P<0.01). Also, children grafted for early BM relapses had a higher P2.-EFS (0.32 vs. 0.11 for the control group P = 0.01). The outcome was similar when children were transplanted after early or late relapse. Also, there was no difference in outcome between the BMT and the chemotherapy group for children with late relapses. We conclude that allogeneic BMT with an HLA-identical sibling donor or other family donor should be performed in children relapsing in bone marrow during therapy or within 6 months of discontinuing therapy.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://doi.org/10.1038/sj.bmt.1701617

Full metadata record

DC FieldValue Language
dc.contributor.authorSchroeder, H-
dc.contributor.authorGustafsson, G-
dc.contributor.authorSaarinen-Pihkala, U M-
dc.contributor.authorGlomstein, A-
dc.contributor.authorJonmundsson, G-
dc.contributor.authorNysom, K-
dc.contributor.authorRingden, O-
dc.contributor.authorMellander, L-
dc.date.accessioned2009-01-13T14:11:03Z-
dc.date.available2009-01-13T14:11:03Z-
dc.date.issued1999-03-01-
dc.date.submitted2009-01-13-
dc.identifier.citationBone Marrow Transplant. 1999, 23(6):555-60en
dc.identifier.issn0268-3369-
dc.identifier.pmid10217185-
dc.identifier.doi10.1038/sj.bmt.1701617-
dc.identifier.urihttp://hdl.handle.net/2336/47361-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThis study compares allogeneic BMT with conventional chemotherapy for childhood ALL in second remission. Seventy-five children were transplanted between July 1981 and December 1995. For each patient two control patients matching the following criteria were selected from the Nordic database of ALL: (1) time of diagnosis, (2) T vs. non-T ALL, (3) site of relapse, (4) initial risk group, (5) sex and (6) relapse < or > or =6 months after cessation of therapy. The minimal time of follow-up was 24 months. Mortality rate in CR2, leukemic relapse rate and the proportion in continued second remission were 16/75 (21%), 22/75 (29%) and 37/75 (50%), respectively. P2.-EFS for the BMT group was significantly better than that for the control group (0.40 vs. 0.23, P = 0.02). Children transplanted for bone marrow relapses in particular had a higher P2.-EFS (0.35 vs. 0.15 for the control group, P<0.01). Also, children grafted for early BM relapses had a higher P2.-EFS (0.32 vs. 0.11 for the control group P = 0.01). The outcome was similar when children were transplanted after early or late relapse. Also, there was no difference in outcome between the BMT and the chemotherapy group for children with late relapses. We conclude that allogeneic BMT with an HLA-identical sibling donor or other family donor should be performed in children relapsing in bone marrow during therapy or within 6 months of discontinuing therapy.en
dc.language.isoenen
dc.publisherNature Publishing Groupen
dc.relation.urlhttp://doi.org/10.1038/sj.bmt.1701617en
dc.subject.meshAdolescenten
dc.subject.meshBone Marrow Transplantationen
dc.subject.meshCase-Control Studiesen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshCyclosporineen
dc.subject.meshFemaleen
dc.subject.meshFinlanden
dc.subject.meshGraft vs Host Diseaseen
dc.subject.meshHumansen
dc.subject.meshIcelanden
dc.subject.meshInfanten
dc.subject.meshMaleen
dc.subject.meshMethotrexateen
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphomaen
dc.subject.meshRemission Inductionen
dc.subject.meshRetrospective Studiesen
dc.subject.meshScandinaviaen
dc.subject.meshTime Factorsen
dc.subject.meshTreatment Outcomeen
dc.titleAllogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countriesen
dc.typeArticleen
dc.contributor.departmentDepartment of Pediatrics, University Hospital of Aarhus, Denmark.en
dc.identifier.journalBone marrow transplantationen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.